<DOC>
	<DOCNO>NCT02476058</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability JNJ-42847922 participant Major Depressive Disorder ( MDD ) .</brief_summary>
	<brief_title>A Safety , Efficacy Biomarker Study JNJ-42847922 Participants With Major Depressive Disorder</brief_title>
	<detailed_description>This multi-center ( one hospital work medical research study ) , randomize ( study medication assign participant chance ) , double-blind ( neither researcher participant know treatment participant receive ) placebo-controlled ( inactive substance ; pretend treatment [ drug ] compare clinical trial drug test drug real effect ) study . This study consist eligibility screen examination ( 28 day 1 day prior first dose administration ) , parallel group treatment phase 10 day 4 week , follow-up period 2 week include 2 follow-up visit . The duration study 12 month . Participants randomly assign receive either JNJ-42847922 , Diphenhydramine Placebo . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>Before randomization , woman must either : 1 ) Not childbearing potential : postmenopausal ; permanently sterilize ; otherwise incapable pregnancy . 2 ) Of childbearing potential practicing highly effective method birth control consistent local regulation regard use birth control method participant participate clinical study : example , establish use oral , injected implant hormonal method contraception ; placement intrauterine device ( IUD ) intrauterine system ( IUS ) combination barrier method : condom spermicidal foam/gel/film/cream/suppository occlusive cap spermicidal foam/gel/film/cream/suppository ; male partner sterilization ; true abstinence . Women must agree continue use method contraception throughout study least 3 month receive last dose study medication Participant Body mass index ( BMI ) must 18 30 kilogram per square meter ( kg/m2 ) inclusive Participant must meet Diagnostic Statistical Manual Mental DisordersIV ( DSMIV ) 5 diagnostic criterion major depressive disorder ( MDD ) without psychotic feature , confirm Mini International Neuropsychiatric Interview ( MINI ) 6.0 ; Participant must Inventory Depressive Symptomatology Clinician rated30 ( IDSC30 ) total score great equal ( &gt; = ) 30 ; Participant either currently antidepressant naive currently treat maximum two concurrent antidepressant . If subject currently treat antidepressant , give optimal dose least 4 week , longer 24 week suboptimal response A man sexually active woman childbearing potential vasectomy must agree use barrier method birth control e.g. , either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository , men must also donate sperm study 3 month receive last dose study drug Participant must willing able adhere prohibition restriction specify protocol Women pregnant breast feeding Participant history malignancy within 5 year screen ( exception squamous basal cell carcinoma skin carcinoma situ cervix , malignancy opinion investigator , concurrence sponsor 's study responsible physician , consider cure minimal risk recurrence ) Participant primary DSM diagnosis general anxiety disorder ( GAD ) , panic disorder , obsessive compulsive disorder ( OCD ) , posttraumatic stress disorder ( PTSD ) , anorexia nervosa , bulimia nervosa . Subjects comorbid GAD , social anxiety disorder ( SAD ) , panic disorder MDD consider primary diagnosis exclude Participant length current major depressive episode ( MDE ) &gt; 24 month despite adequate treatment Participant fail 2 treatment different pharmacological mode action despite adequate dose duration previous , current depressive episode</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>JNJ-42847922</keyword>
	<keyword>Diphenhydramine</keyword>
	<keyword>Placebo</keyword>
</DOC>